BVF PARTNERS L P/IL Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for BVF PARTNERS L P/IL.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BVF PARTNERS L P/IL. BVF PARTNERS L P/IL is 10% Owner in LIGAND PHARMACEUTICALS INC ($LGND) and 10% Owner in AVIGEN INC \DE ($AVGN) and 10% Owner in NEUROCRINE BIOSCIENCES INC ($NBIX) and 10% Owner in ARQULE INC ($ARQL) and 10% Owner in CURIS INC ($CRIS) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in EPIRUS Biopharmaceuticals, Inc. ($CRXX).
Latest Insider Trading Transactions of BVF PARTNERS L P/IL
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ARQL, AVGN, CRIS, DVAX, CRXX, LGND, NBIX
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 01 2009 | DVAX | DYNAVAX TECHNOLOGI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 1.30 | 13,000 | 16,900 | 8,110,657 | 8.1 M to 8.1 M (-0.16 %) |
May 01 2009 | DVAX | DYNAVAX TECHNOLOGI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 1.30 | 4,000 | 5,200 | 8,123,657 | 8.1 M to 8.1 M (-0.05 %) |
May 01 2009 | DVAX | DYNAVAX TECHNOLOGI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 1.30 | 5,000 | 6,500 | 8,127,657 | 8.1 M to 8.1 M (-0.06 %) |
Apr 29 2009 | CRIS | CURIS INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 1.15 | 1,741,000 | 2,002,150 | 5,951,716 | 7.7 M to 6 M (-22.63 %) |
Apr 29 2009 | CRIS | CURIS INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 1.15 | 502,000 | 577,300 | 7,692,716 | 8.2 M to 7.7 M (-6.13 %) |
Apr 29 2009 | CRIS | CURIS INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 1.15 | 727,000 | 836,050 | 8,194,716 | 8.9 M to 8.2 M (-8.15 %) |
Jan 26 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.10 | 6,000 | 18,586 | 5,946,547 | 5.9 M to 5.9 M (+0.10 %) |
Jan 26 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.10 | 2,000 | 6,195 | 5,940,547 | 5.9 M to 5.9 M (+0.03 %) |
Jan 26 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.10 | 1,000 | 3,098 | 5,938,547 | 5.9 M to 5.9 M (+0.02 %) |
Jan 26 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.10 | 4,000 | 12,400 | 5,937,547 | 5.9 M to 5.9 M (+0.07 %) |
Jan 26 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.10 | 1,000 | 3,100 | 5,933,547 | 5.9 M to 5.9 M (+0.02 %) |
Jan 26 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.10 | 1,900 | 5,890 | 5,932,547 | 5.9 M to 5.9 M (+0.03 %) |
Jan 22 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.06 | 15,000 | 45,891 | 5,930,647 | 5.9 M to 5.9 M (+0.25 %) |
Jan 22 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.06 | 4,000 | 12,238 | 5,915,647 | 5.9 M to 5.9 M (+0.07 %) |
Jan 22 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.06 | 6,200 | 18,968 | 5,911,647 | 5.9 M to 5.9 M (+0.10 %) |
Jan 22 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.08 | 45,000 | 138,681 | 5,905,447 | 5.9 M to 5.9 M (+0.77 %) |
Jan 22 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.08 | 12,000 | 36,982 | 5,860,447 | 5.8 M to 5.9 M (+0.21 %) |
Jan 22 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.08 | 18,000 | 55,472 | 5,848,447 | 5.8 M to 5.8 M (+0.31 %) |
Jan 20 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.05 | 4,000 | 12,209 | 5,830,447 | 5.8 M to 5.8 M (+0.07 %) |
Jan 20 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.05 | 1,000 | 3,052 | 5,826,447 | 5.8 M to 5.8 M (+0.02 %) |
Jan 20 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.05 | 2,400 | 7,325 | 5,825,447 | 5.8 M to 5.8 M (+0.04 %) |
Jan 02 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.80 | 7,000 | 19,600 | 5,823,047 | 5.8 M to 5.8 M (+0.12 %) |
Jan 02 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.80 | 2,000 | 5,600 | 5,816,047 | 5.8 M to 5.8 M (+0.03 %) |
Jan 02 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.80 | 1,600 | 4,480 | 5,814,047 | 5.8 M to 5.8 M (+0.03 %) |
Dec 03 2008 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.35 | 59,000 | 138,402 | 5,812,447 | 5.8 M to 5.8 M (+1.03 %) |
Dec 03 2008 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.35 | 16,000 | 37,533 | 5,753,447 | 5.7 M to 5.8 M (+0.28 %) |
Dec 03 2008 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.35 | 24,400 | 57,238 | 5,737,447 | 5.7 M to 5.7 M (+0.43 %) |
Nov 26 2008 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.45 | 32,000 | 78,387 | 5,713,047 | 5.7 M to 5.7 M (+0.56 %) |
Nov 26 2008 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.45 | 9,000 | 22,046 | 5,681,047 | 5.7 M to 5.7 M (+0.16 %) |
Nov 26 2008 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.45 | 13,400 | 32,825 | 5,672,047 | 5.7 M to 5.7 M (+0.24 %) |
Dec 09 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.98 | 17,000 | 33,699 | 13,537,275 | 13.5 M to 13.5 M (+0.13 %) |
Dec 09 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.98 | 5,000 | 9,912 | 13,520,275 | 13.5 M to 13.5 M (+0.04 %) |
Dec 09 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.98 | 6,283 | 12,455 | 13,515,275 | 13.5 M to 13.5 M (+0.05 %) |
Dec 05 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.04 | 57,000 | 116,046 | 13,508,992 | 13.5 M to 13.5 M (+0.42 %) |
Dec 05 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.04 | 16,000 | 32,574 | 13,451,992 | 13.4 M to 13.5 M (+0.12 %) |
Dec 05 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.04 | 23,300 | 47,436 | 13,435,992 | 13.4 M to 13.4 M (+0.17 %) |
Dec 05 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.95 | 16,000 | 31,194 | 13,412,692 | 13.4 M to 13.4 M (+0.12 %) |
Dec 05 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.95 | 5,000 | 9,748 | 13,396,692 | 13.4 M to 13.4 M (+0.04 %) |
Dec 05 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.95 | 6,739 | 13,138 | 13,391,692 | 13.4 M to 13.4 M (+0.05 %) |
Dec 03 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.90 | 115,000 | 218,040 | 13,384,953 | 13.3 M to 13.4 M (+0.87 %) |
Dec 03 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.90 | 32,000 | 60,672 | 13,269,953 | 13.2 M to 13.3 M (+0.24 %) |
Dec 03 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.90 | 46,000 | 87,216 | 13,237,953 | 13.2 M to 13.2 M (+0.35 %) |
Dec 03 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.86 | 79,000 | 147,248 | 13,191,953 | 13.1 M to 13.2 M (+0.60 %) |
Dec 03 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.86 | 22,000 | 41,006 | 13,112,953 | 13.1 M to 13.1 M (+0.17 %) |
Dec 03 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.86 | 30,700 | 57,222 | 13,090,953 | 13.1 M to 13.1 M (+0.24 %) |
Dec 01 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.99 | 144,000 | 287,050 | 13,060,253 | 12.9 M to 13.1 M (+1.11 %) |
Dec 01 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.99 | 40,000 | 79,736 | 12,916,253 | 12.9 M to 12.9 M (+0.31 %) |
Dec 01 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.99 | 56,600 | 112,826 | 12,876,253 | 12.8 M to 12.9 M (+0.44 %) |
Dec 01 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.97 | 242,000 | 477,393 | 12,819,653 | 12.6 M to 12.8 M (+1.92 %) |
Dec 01 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.97 | 68,000 | 134,144 | 12,577,653 | 12.5 M to 12.6 M (+0.54 %) |
Dec 01 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.97 | 98,000 | 193,325 | 12,509,653 | 12.4 M to 12.5 M (+0.79 %) |
Dec 01 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.93 | 560,000 | 1,080,800 | 12,411,653 | 11.9 M to 12.4 M (+4.73 %) |
Dec 01 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.93 | 156,000 | 301,080 | 11,851,653 | 11.7 M to 11.9 M (+1.33 %) |
Dec 01 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.93 | 226,000 | 436,180 | 11,695,653 | 11.5 M to 11.7 M (+1.97 %) |
Nov 26 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.77 | 210,000 | 372,099 | 11,469,653 | 11.3 M to 11.5 M (+1.87 %) |
Nov 26 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.77 | 59,000 | 104,542 | 11,259,653 | 11.2 M to 11.3 M (+0.53 %) |
Nov 26 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.77 | 84,000 | 148,840 | 11,200,653 | 11.1 M to 11.2 M (+0.76 %) |
Nov 26 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.01 | 85,000 | 170,935 | 11,116,653 | 11 M to 11.1 M (+0.77 %) |
Nov 26 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.01 | 24,000 | 48,264 | 11,031,653 | 11 M to 11 M (+0.22 %) |
Nov 26 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.01 | 34,000 | 68,374 | 11,007,653 | 11 M to 11 M (+0.31 %) |
Nov 24 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.78 | 111,000 | 197,192 | 10,973,653 | 10.9 M to 11 M (+1.02 %) |
Nov 24 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.78 | 31,000 | 55,072 | 10,862,653 | 10.8 M to 10.9 M (+0.29 %) |
Nov 24 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.78 | 44,744 | 79,488 | 10,831,653 | 10.8 M to 10.8 M (+0.41 %) |
Nov 24 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.26 | 6,000 | 7,585 | 10,786,909 | 10.8 M to 10.8 M (+0.06 %) |
Nov 24 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.26 | 2,000 | 2,528 | 10,780,909 | 10.8 M to 10.8 M (+0.02 %) |
Nov 24 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.26 | 1,200 | 1,517 | 10,778,909 | 10.8 M to 10.8 M (+0.01 %) |
Nov 20 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.39 | 20,000 | 27,822 | 10,777,709 | 10.8 M to 10.8 M (+0.19 %) |
Nov 20 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.39 | 5,000 | 6,956 | 10,757,709 | 10.8 M to 10.8 M (+0.05 %) |
Nov 20 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.39 | 8,000 | 11,129 | 10,752,709 | 10.7 M to 10.8 M (+0.07 %) |
Nov 20 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.38 | 48,000 | 66,360 | 10,744,709 | 10.7 M to 10.7 M (+0.45 %) |
Nov 20 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.38 | 13,000 | 17,973 | 10,696,709 | 10.7 M to 10.7 M (+0.12 %) |
Nov 20 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.38 | 20,400 | 28,203 | 10,683,709 | 10.7 M to 10.7 M (+0.19 %) |
Nov 18 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.33 | 55,000 | 73,128 | 10,663,309 | 10.6 M to 10.7 M (+0.52 %) |
Nov 18 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.33 | 15,000 | 19,944 | 10,608,309 | 10.6 M to 10.6 M (+0.14 %) |
Nov 18 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.33 | 22,000 | 29,251 | 10,593,309 | 10.6 M to 10.6 M (+0.21 %) |
Nov 18 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.30 | 125,000 | 162,500 | 10,571,309 | 10.4 M to 10.6 M (+1.20 %) |
Nov 18 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.30 | 34,000 | 44,200 | 10,446,309 | 10.4 M to 10.4 M (+0.33 %) |
Nov 18 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.30 | 50,000 | 65,000 | 10,412,309 | 10.4 M to 10.4 M (+0.48 %) |
Nov 18 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 1,000 | 1,350 | 10,362,309 | 10.4 M to 10.4 M (+0.01 %) |
Nov 14 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.34 | 56,000 | 75,202 | 10,361,309 | 10.3 M to 10.4 M (+0.54 %) |
Nov 14 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.34 | 16,000 | 21,486 | 10,305,309 | 10.3 M to 10.3 M (+0.16 %) |
Nov 14 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.34 | 22,000 | 29,544 | 10,289,309 | 10.3 M to 10.3 M (+0.21 %) |
Nov 14 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 9,000 | 12,138 | 10,267,309 | 10.3 M to 10.3 M (+0.09 %) |
Nov 14 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 2,000 | 2,697 | 10,258,309 | 10.3 M to 10.3 M (+0.02 %) |
Nov 14 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 3,511 | 4,735 | 10,256,309 | 10.3 M to 10.3 M (+0.03 %) |
Nov 12 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.39 | 100,000 | 139,070 | 10,252,798 | 10.2 M to 10.3 M (+0.98 %) |
Nov 12 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.39 | 28,000 | 38,940 | 10,152,798 | 10.1 M to 10.2 M (+0.28 %) |
Nov 12 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.39 | 39,850 | 55,419 | 10,124,798 | 10.1 M to 10.1 M (+0.40 %) |
Nov 12 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.36 | 119,000 | 162,316 | 10,084,948 | 10 M to 10.1 M (+1.19 %) |
Nov 12 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.36 | 33,000 | 45,012 | 9,965,948 | 9.9 M to 10 M (+0.33 %) |
Nov 12 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.36 | 46,000 | 62,744 | 9,932,948 | 9.9 M to 9.9 M (+0.47 %) |
Nov 12 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.41 | 67,000 | 94,463 | 9,886,948 | 9.8 M to 9.9 M (+0.68 %) |
Nov 12 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.41 | 19,000 | 26,788 | 9,819,948 | 9.8 M to 9.8 M (+0.19 %) |
Nov 12 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.41 | 27,000 | 38,067 | 9,800,948 | 9.8 M to 9.8 M (+0.28 %) |
Dec 09 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.57 | 28,000 | 15,960 | 10,008,871 | 10 M to 10 M (+0.28 %) |
Dec 09 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.57 | 8,000 | 4,560 | 9,980,871 | 10 M to 10 M (+0.08 %) |
Dec 09 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.57 | 11,000 | 6,270 | 9,972,871 | 10 M to 10 M (+0.11 %) |
Dec 09 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.57 | 3,000 | 1,709 | 9,961,871 | 10 M to 10 M (+0.03 %) |
Dec 09 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.57 | 1,000 | 570 | 9,958,871 | 10 M to 10 M (+0.01 %) |
Dec 09 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.57 | 1,700 | 969 | 9,957,871 | 10 M to 10 M (+0.02 %) |
Dec 09 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.57 | 878,000 | 500,460 | 9,956,171 | 9.1 M to 10 M (+9.67 %) |
Dec 09 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.57 | 245,000 | 139,650 | 9,078,171 | 8.8 M to 9.1 M (+2.77 %) |
Dec 09 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.57 | 354,872 | 202,277 | 8,833,171 | 8.5 M to 8.8 M (+4.19 %) |
Dec 05 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.55 | 6,000 | 3,300 | 8,478,299 | 8.5 M to 8.5 M (+0.07 %) |
Dec 05 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.55 | 2,000 | 1,100 | 8,472,299 | 8.5 M to 8.5 M (+0.02 %) |
Dec 05 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.55 | 2,300 | 1,265 | 8,470,299 | 8.5 M to 8.5 M (+0.03 %) |
Dec 05 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.54 | 8,000 | 4,308 | 8,467,999 | 8.5 M to 8.5 M (+0.09 %) |
Dec 05 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.54 | 2,000 | 1,077 | 8,459,999 | 8.5 M to 8.5 M (+0.02 %) |
Dec 05 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.54 | 3,400 | 1,831 | 8,457,999 | 8.5 M to 8.5 M (+0.04 %) |
Dec 03 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.55 | 6,000 | 3,279 | 8,454,599 | 8.4 M to 8.5 M (+0.07 %) |
Dec 03 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.55 | 2,000 | 1,093 | 8,448,599 | 8.4 M to 8.4 M (+0.02 %) |
Dec 03 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.55 | 1,800 | 984 | 8,446,599 | 8.4 M to 8.4 M (+0.02 %) |
Dec 03 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.55 | 16,000 | 8,800 | 8,444,799 | 8.4 M to 8.4 M (+0.19 %) |
Dec 03 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.55 | 4,000 | 2,200 | 8,428,799 | 8.4 M to 8.4 M (+0.05 %) |
Dec 03 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.55 | 6,800 | 3,740 | 8,424,799 | 8.4 M to 8.4 M (+0.08 %) |
Dec 01 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.49 | 4,000 | 1,976 | 8,417,999 | 8.4 M to 8.4 M (+0.05 %) |
Dec 01 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.49 | 1,000 | 494 | 8,413,999 | 8.4 M to 8.4 M (+0.01 %) |
Dec 01 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.49 | 1,600 | 790 | 8,412,999 | 8.4 M to 8.4 M (+0.02 %) |
Nov 26 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.47 | 7,000 | 3,275 | 8,411,399 | 8.4 M to 8.4 M (+0.08 %) |
Nov 26 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.47 | 2,000 | 936 | 8,404,399 | 8.4 M to 8.4 M (+0.02 %) |
Nov 26 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.47 | 3,300 | 1,544 | 8,402,399 | 8.4 M to 8.4 M (+0.04 %) |
Nov 25 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.45 | 49,000 | 22,050 | 8,399,099 | 8.4 M to 8.4 M (+0.59 %) |
Nov 25 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.45 | 14,000 | 6,300 | 8,350,099 | 8.3 M to 8.4 M (+0.17 %) |
Nov 25 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.45 | 20,100 | 9,045 | 8,336,099 | 8.3 M to 8.3 M (+0.24 %) |
Nov 25 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.45 | 7,000 | 3,150 | 8,315,999 | 8.3 M to 8.3 M (+0.08 %) |
Nov 25 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.45 | 2,000 | 900 | 8,308,999 | 8.3 M to 8.3 M (+0.02 %) |
Nov 25 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.45 | 3,000 | 1,350 | 8,306,999 | 8.3 M to 8.3 M (+0.04 %) |
Nov 18 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.60 | 6,000 | 3,578 | 8,303,999 | 8.3 M to 8.3 M (+0.07 %) |
Nov 18 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.60 | 2,000 | 1,193 | 8,297,999 | 8.3 M to 8.3 M (+0.02 %) |
Nov 18 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.60 | 1,200 | 716 | 8,295,999 | 8.3 M to 8.3 M (+0.01 %) |
Nov 14 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.60 | 6,000 | 3,600 | 8,294,799 | 8.3 M to 8.3 M (+0.07 %) |
Nov 14 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.60 | 2,000 | 1,200 | 8,288,799 | 8.3 M to 8.3 M (+0.02 %) |
Nov 14 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.60 | 1,000 | 600 | 8,286,799 | 8.3 M to 8.3 M (+0.01 %) |
Nov 14 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.60 | 2,000 | 1,200 | 8,285,799 | 8.3 M to 8.3 M (+0.02 %) |
Nov 14 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.60 | 1,000 | 600 | 8,283,799 | 8.3 M to 8.3 M (+0.01 %) |
Nov 14 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.60 | 600 | 360 | 8,282,799 | 8.3 M to 8.3 M (+0.01 %) |
Nov 12 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.60 | 83,000 | 49,659 | 8,282,199 | 8.2 M to 8.3 M (+1.01 %) |
Nov 12 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.60 | 23,000 | 13,761 | 8,199,199 | 8.2 M to 8.2 M (+0.28 %) |
Nov 12 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.60 | 33,100 | 19,804 | 8,176,199 | 8.1 M to 8.2 M (+0.41 %) |
Nov 12 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.58 | 8,000 | 4,640 | 8,143,099 | 8.1 M to 8.1 M (+0.10 %) |
Nov 12 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.58 | 2,000 | 1,160 | 8,135,099 | 8.1 M to 8.1 M (+0.02 %) |
Nov 12 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.58 | 4,000 | 2,320 | 8,133,099 | 8.1 M to 8.1 M (+0.05 %) |
Nov 12 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.58 | 65,000 | 37,486 | 8,129,099 | 8.1 M to 8.1 M (+0.81 %) |
Nov 12 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.58 | 18,000 | 10,381 | 8,064,099 | 8 M to 8.1 M (+0.22 %) |
Nov 12 2008 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.58 | 26,700 | 15,398 | 8,046,099 | 8 M to 8 M (+0.33 %) |
Nov 20 2008 | AVGN | AVIGEN INC \DE | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.75 | 18,000 | 13,489 | 8,310,015 | 8.3 M to 8.3 M (+0.22 %) |
Nov 20 2008 | AVGN | AVIGEN INC \DE | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.75 | 5,000 | 3,747 | 8,292,015 | 8.3 M to 8.3 M (+0.06 %) |
Nov 20 2008 | AVGN | AVIGEN INC \DE | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.75 | 7,300 | 5,471 | 8,287,015 | 8.3 M to 8.3 M (+0.09 %) |
Nov 20 2008 | AVGN | AVIGEN INC \DE | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.74 | 24,000 | 17,652 | 8,279,715 | 8.3 M to 8.3 M (+0.29 %) |
Nov 20 2008 | AVGN | AVIGEN INC \DE | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.74 | 7,000 | 5,149 | 8,255,715 | 8.2 M to 8.3 M (+0.08 %) |